Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus neoadjuvant radiotherapy versus pembrolizumab plus neoadjuvant chemotherapy for resectable locally advanced thoracic esophageal squamous cell carcinoma
ChiCTR2100051333Phase 3Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Mar 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: Main pathological remission rate and Pathological complete remission rate. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2100051333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051333.